Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 19, 2017. The document serves as a transaction notification reporting changes in shareholdings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions relate to the re-investment of dividends paid on April 13, 2017, under the Company's 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transaction metrics for executive compensation plans.
| Instrument | Transaction Price | Transaction Date |
|---|---|---|
| Ordinary Shares (GBP) | £16.47 | April 18, 2017 |
| American Depositary Shares (USD) | $41.81 | April 18, 2017 |
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares and ADSs for eleven senior executives. These increases resulted from the automatic re-investment of dividends into the 2009 Deferred Annual Bonus Plan. No other material changes to the company's operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of insider trading activity related to a specific compensation plan.
Important Facts for Investors
- Transaction Nature: All reported transactions were non-discretionary increases in shareholdings due to dividend re-investment, not open market purchases or sales.
- Executives Involved: The filing covers transactions for the CEO (Ms. E. Walmsley), CFO (Mr. S. Dingemans), and other senior leaders including the Presidents of Global Pharmaceuticals, Vaccines, and R&D.
- Share Prices: The transactions occurred at a price of £16.47 per Ordinary Share and $41.81 per ADS on April 18, 2017.
- Scope: This document does not provide financial results for the quarter or year; investors should refer to Form 20-F or quarterly earnings releases for performance metrics.